Skip to main content

Table 3 Stimulating growth factor 2 and interleukin-33 levels in patients with myocardial infarctions according to the presence of visceral obesity

From: Relationships between epicardial adipose tissue thickness and adipo-fibrokine indicator profiles post-myocardial infarction

Parameter Control group
n = 30
Patients without visceral obesity
n = 29
Patients with visceral obesity
n = 59
Day 1 Day 12 1 year Day 1 Day 12 1 year
ST2, ng/mL 18.81 (15.12, 21.03) 66.7 (26.2, 157.6)a 24.5 (17.1, 34.8)a 21.7 (13.9: 30.2)a,b,с 46.5 (21.8: 102.0)a,е 22.3 (16.4: 27.9)a,е 23.7 (16.4: 32.4)a,b,с
IL-33, ng/mL 0.57 (0.29, 0.69) 5.3 (3.6, 9.9)a 3.6 (2.8, 4.4)a 9.9 (8.4, 11.3)a,b,с,d 4.49 (4.0, 5.1)a,е 3.8 (3.2, 4.3)a,е 9.9 (9.7, 9.1: 11.3)a,b,с,d
  1. ST stimulating growth factor, IL interleukin
  2. The data presented are the medians and the 25th and 75th quartiles. ap < 0.05 for comparisons with the control group; bp < 0.05 for comparisons between the levels measured on days 1 and 12 post-myocardial infarction (MI); cp < 0.05 for comparisons between the levels measured on day 1 and at 1-year post-MI; dp < 0.05 for comparisons between the levels measured on day 12 and at 1-year post-MI; ep < 0.05 for comparisons between the study groups